Bruker Corporation announced on April 25, 2025, significant advancements in spatial biology and multiomics research at the 2025 American Association for Cancer Research (AACR) General Meeting. These innovations build upon previous announcements at AGBT 2025.
The commercial CosMx SMI and AtoMx® SIP platforms will be upgraded to an integrated 2.0 software, delivering up to a 2X increase in RNA detection efficiency across all commercial RNA assays. This upgrade will also enable whole transcriptome analysis ahead of commercial assay shipments in summer 2025.
The CosMx 2.0 update will unlock same-slide multiomics, allowing oncology researchers to simultaneously analyze the whole transcriptome (~19,000 targets) and immuno-oncology related proteins (up to 76 proteins) within the same cell. Additionally, the nCounter platform will offer new multiomic capabilities, enabling bulk measurement of RNA and protein from the same sample in a single run.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.